$ABT announced its Q1 2025 earnings, reporting an EPS of $1.09, slightly beating expectations, while revenue of $10.36B fell short by $58.96M. Despite this, sales grew 3.95% YoY, revealing solid performance in nutrition and medical devices. The risk of tariffs impacting financials was acknowledged. Highlights: โ๏ธ Gross margin up +140bps, ยฐ๐ 12.5% growth in medical devices, and forecast earnings per share of $1.23 to $1.27 for the next quarter. Future opportunities include expanding biosimilars and new diabetes products. Check details at valueverge.com/ABT.